Headquarters: Cambridge, Massachusetts, USA
Ticker: CERE (NASDAQ)
Founded: 2020 (spun off from Pfizer)
Pipeline Focus: [Parkinson's Disease](/diseases/parkinsons-disease) disease, epilepsy, mood disorders
Overview
Mermaid diagram (expand to render)
Cerevel Therapeutics is a neuroscience-focused biotechnology company that was spun off from Pfizer in 2020 and went public in 2021. The company leverages its deep expertise in receptor selectivity and brain penetration to develop novel therapies for neurological and psychiatric disorders. Cerevel's lead program, CVN424, represents a novel approach to [Parkinson's Disease](/diseases/parkinsons-disease) disease treatment through selective dopamine D1/D5 receptor activation["@cvn"].
Cerevel's pipeline focuses on areas of high unmet need in neuroscience, including movement disorders, epilepsy, and mood disorders. The company's strategy combines internal discovery with strategic partnerships to advance its portfolio of novel molecules with differentiated pharmacology^2].
CVN424 represents a novel approach to treating [Parkinson's Disease](/diseases/parkinsons-disease) disease motor symptoms through selective activation of dopamine D1 and D5 receptors. Unlike current dopamine agonists that broadly stimulate dopamine receptors, CVN424's selectivity profile may provide motor symptom relief with potentially reduced side effects including dyskinesia^3].
Clinical Development:
Phase 1: Completed, demonstrating safety and target engagement
Phase 2: Ongoing in [Parkinson's Disease](/diseases/parkinsons-disease) disease patients
Differentiation:
Selective D1/D5 agonist vs. non-selective dopamine agonists
Potential for improved motor symptom control
Reduced risk of dyskinesia development
CVN231
Mechanism: Undisclosed CNS target
Stage: Phase 1
Status: Clinical
CVN231 is Cerevel's second [Parkinson's Disease](/diseases/parkinsons-disease) disease program, currently in Phase 1 clinical trials. Additional details about the mechanism and target remain undisclosed^4].
[Multiple System Atrophy](/diseases/multiple-system-atrophy) Relevance
Cerevel's dopamine-focused pipeline has potential relevance to [Multiple System Atrophy](/diseases/multiple-system-atrophy):
CVN424 (D1/D5 agonist): May provide symptomatic benefit for MSA-P variant patients with parkinsonism, as the selective D1/D5 mechanism could potentially address dopamine deficiency in striatonigral degeneration
Motor symptom management: Cerevel's focus on movement disorders positions the company to potentially expand into MSA symptom management
Partner ecosystem: Pfizer partnership provides resources for potential MSA program development